Literature DB >> 24114660

Antioxidant effect of doxycycline decreases MMP activity and blood pressure in SHR.

Raquel C Antonio1, Carla S Ceron, Elen Rizzi, Eduardo B Coelho, Jose E Tanus-Santos, Raquel F Gerlach.   

Abstract

Increased matrix metalloproteinase (MMP) levels are involved in vascular remodeling of hypertension. In this study, we hypothesized that doxycycline (a MMP inhibitor) could exert antioxidant effects, reverse establish vascular remodeling, and lower blood pressure in spontaneously hypertensive rats (SHR). SHR and Wistar-Kyoto rats received either doxycycline at 30 mg/kg/day by gavage or vehicle. Systolic blood pressure (SBP) was assessed weekly by tail cuff. After 5 weeks of treatment, morphologic changes in the aortic wall were studied in hematoxylin/eosin sections. MMP activity and expression were determined by in situ zymography using DQ gelatin and immunofluorescence for MMP-2. Dihydroethidium was used to evaluate aortic reactive oxygen species (ROS) production by fluorescence microscopy. Doxycycline reduced SBP by 25 mmHg. However, the antihypertensive effects were not associated with significant reversal of hypertension-induced vascular hypertrophy. SHR showed increased aortic MMP-2 levels which co-localized with higher aortic MMP activity and ROS levels, and all those biochemical alterations associated with hypertension were blunted by treatment with doxycycline. These results show that MMP inhibition with doxycycline in SHR with established hypertension resulted in antioxidant effects, lower gelatinolytic activity, and antihypertensive effects which were not associated with reversal of hypertension-induced vascular remodeling.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24114660     DOI: 10.1007/s11010-013-1848-7

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  33 in total

1.  Matrix metalloproteinases cleave the beta2-adrenergic receptor in spontaneously hypertensive rats.

Authors:  Stephen F Rodrigues; Edward D Tran; Zuleica B Fortes; Geert W Schmid-Schönbein
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-04-09       Impact factor: 4.733

Review 2.  Circulating matrix metalloproteinases and their inhibitors in hypertension.

Authors:  Vanessa Fontana; Pamela S Silva; Raquel F Gerlach; Jose E Tanus-Santos
Journal:  Clin Chim Acta       Date:  2012-01-08       Impact factor: 3.786

3.  Hemodynamic benefits of matrix metalloproteinase-9 inhibition by doxycycline during experimental acute pulmonary embolism.

Authors:  Ana C T Palei; Rafael A G Zaneti; Geisa M Fortuna; Raquel F Gerlach; Jose E Tanus-Santos
Journal:  Angiology       Date:  2005 Sep-Oct       Impact factor: 3.619

Review 4.  Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly.

Authors:  Zorina S Galis; Jaikirshan J Khatri
Journal:  Circ Res       Date:  2002-02-22       Impact factor: 17.367

5.  Consistent alterations of circulating matrix metalloproteinases levels in untreated hypertensives and in spontaneously hypertensive rats: a relevant pharmacological target.

Authors:  Vanessa Fontana; Pamela S Silva; Vanessa A Belo; Raquel C Antonio; Carla S Ceron; Celso Biagi; Raquel F Gerlach; Jose E Tanus-Santos
Journal:  Basic Clin Pharmacol Toxicol       Date:  2011-04-04       Impact factor: 4.080

6.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

7.  Recombinant human matrix metalloproteinase-2 impairs cardiovascular β-adrenergic responses.

Authors:  Karina C Ferraz; Ozélia Sousa-Santos; Evandro M Neto-Neves; Elen Rizzi; Jaqueline J Muniz; Raquel F Gerlach; Jose E Tanus-Santos
Journal:  Basic Clin Pharmacol Toxicol       Date:  2012-09-29       Impact factor: 4.080

8.  Reactive oxygen species activate and tetracyclines inhibit rat osteoblast collagenase.

Authors:  N S Ramamurthy; A T Vernillo; R A Greenwald; H M Lee; T Sorsa; L M Golub; B R Rifkin
Journal:  J Bone Miner Res       Date:  1993-10       Impact factor: 6.741

9.  Role of NF-kappaB in flow-induced vascular remodeling.

Authors:  Yves Castier; Bhama Ramkhelawon; Stéphanie Riou; Alain Tedgui; Stephanie Lehoux
Journal:  Antioxid Redox Signal       Date:  2009-07       Impact factor: 8.401

10.  Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats.

Authors:  Marcio L L Martinez; Michele M Castro; Elen Rizzi; Karla Fernandes; Caroline Demacq; Lusiane M Bendhack; Raquel F Gerlach; Jose E Tanus-Santos
Journal:  Eur J Pharmacol       Date:  2008-07-02       Impact factor: 4.432

View more
  11 in total

1.  Doxycycline shows dose-dependent changes in hernia repair strength after mesh repair.

Authors:  Job C Tharappel; Jennifer W Harris; Brittany A Zwischenberger; Salomon M Levy; David A Puleo; J Scott Roth
Journal:  Surg Endosc       Date:  2015-08-12       Impact factor: 4.584

Review 2.  Gut Microbiome and Neuroinflammation in Hypertension.

Authors:  Elaine M Richards; Jing Li; Bruce R Stevens; Carl J Pepine; Mohan K Raizada
Journal:  Circ Res       Date:  2022-02-03       Impact factor: 17.367

3.  Brain targeted oral delivery of doxycycline hydrochloride encapsulated Tween 80 coated chitosan nanoparticles against ketamine induced psychosis: behavioral, biochemical, neurochemical and histological alterations in mice.

Authors:  Monu Yadav; Milind Parle; Nidhi Sharma; Sameer Dhingra; Neha Raina; Deepak Kumar Jindal
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

4.  Matrix metalloproteinase-9 expression is enhanced in renal parietal epithelial cells of zucker diabetic Fatty rats and is induced by albumin in in vitro primary parietal cell culture.

Authors:  Yuanyuan Zhang; Jasmine George; Yun Li; Rebecca Olufade; Xueying Zhao
Journal:  PLoS One       Date:  2015-04-07       Impact factor: 3.240

5.  Repurposing doxycycline for synucleinopathies: remodelling of α-synuclein oligomers towards non-toxic parallel beta-sheet structured species.

Authors:  Florencia González-Lizárraga; Sergio B Socías; César L Ávila; Clarisa M Torres-Bugeau; Leandro R S Barbosa; Andres Binolfi; Julia E Sepúlveda-Díaz; Elaine Del-Bel; Claudio O Fernandez; Dulce Papy-Garcia; Rosangela Itri; Rita Raisman-Vozari; Rosana N Chehín
Journal:  Sci Rep       Date:  2017-02-03       Impact factor: 4.379

6.  Doxycycline protects against ROS-induced mitochondrial fragmentation and ISO-induced heart failure.

Authors:  Adam Riba; Laszlo Deres; Krisztian Eros; Aliz Szabo; Klara Magyar; Balazs Sumegi; Kalman Toth; Robert Halmosi; Eszter Szabados
Journal:  PLoS One       Date:  2017-04-06       Impact factor: 3.240

7.  Matrix metalloproteinase-2-induced epidermal growth factor receptor transactivation impairs redox balance in vascular smooth muscle cells and facilitates vascular contraction.

Authors:  Alejandro F Prado; Laena Pernomian; Aline Azevedo; Rute A P Costa; Elen Rizzi; Junia Ramos; Adriana F Paes Leme; Lusiane M Bendhack; Jose E Tanus-Santos; Raquel F Gerlach
Journal:  Redox Biol       Date:  2018-07-09       Impact factor: 11.799

8.  Doxycycline Decreases Atherosclerotic Lesions in the Aorta of ApoE-⁄- and Ovariectomized Mice with Correlation to Reduced MMP-2 Activity.

Authors:  Keuri E Rodrigues; Aline Azevedo; Pricila R Gonçalves; Maria H B Pontes; Gustavo M Alves; Ruan R Oliveira; Cristine B Amarante; João P M Issa; Raquel F Gerlach; Alejandro F Prado
Journal:  Int J Mol Sci       Date:  2022-02-25       Impact factor: 5.923

Review 9.  Matrix Metalloproteinase 2 as a Pharmacological Target in Heart Failure.

Authors:  Pricila Rodrigues Gonçalves; Lisandra Duarte Nascimento; Raquel Fernanda Gerlach; Keuri Eleutério Rodrigues; Alejandro Ferraz Prado
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-25

10.  Protective outcomes of low-dose doxycycline on renal function of Wistar rats subjected to acute ischemia/reperfusion injury.

Authors:  Aline L Cortes; Sabrina R Gonsalez; Lilimar S Rioja; Simone S C Oliveira; André L S Santos; Minolfa C Prieto; Paulo A Melo; Lucienne S Lara
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-10-05       Impact factor: 5.187

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.